At Orphalan we identify, develop and provide access to innovative treatments for patients with rare diseases
An experienced pharmaceutical development team
At Orphalan our research and development strategy focuses on the needs of the patient. Our mission is to identify and develop innovative therapies for patients, in the hope of making a meaningful difference to their lives.
We work in rare diseases. There are over 7,000 known rare diseases. We have selected to develop our first product in Wilson’s disease, a disease affecting around 1 in every 30,000 of the worldwide population. Our treatment, Cuprior® (trientine tetrahydrochloride) has been developed and approved for the treatment of Wilsons Disease in EU, EEA, UK and Saudi Arabia.
We interact with a network of leading experts and work with scientists, academic institutions, and companies with innovative technologies and products to enable their development and commercialization.
Cuprior Development Plan
EU – Patients intolerant to D-Penicillamine